2-chlorobenzylazide | 63777-70-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chlorobenzylazide
• 英文别名: 1-(azidomethyl)-2-chlorobenzene；o-chlorobenzyl azide
• CAS: 63777-70-8
• 化学式: C₇H₆ClN₃
• mdl: MFCD11637163
• 分子量: 167.598
• InChiKey: BOSNISRGGXSMHE-UHFFFAOYSA-N

物化性质

• 闪点：
  -30℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  14.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2929909090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 1-(Azidomethyl)-2-chlorobenzene solution

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Flammable liquids (Category 2)
Skin irritation (Category 2)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Highly flammable. Irritating to skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
Highly flammable liquid and vapour.
Causes skin irritation.
Precautionary statement(s)
Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R11 Highly flammable.
R38 Irritating to skin.
S-phrase(s)
S16 Keep away from sources of ignition - No smoking.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Mixtures
Component Classification Concentration
tert-Butyl methyl ether
CAS-No. 1634-04-4 Flam. Liq. 2; Skin Irrit. 2; 50 - 100 %
EC-No. 216-653-1 H225, H315
Index-No. 603-181-00-X
F, Xi, R11 - R38
1-(Azidomethyl)-2-chlorobenzene
CAS-No. 63777-70-8 Skin Irrit. 2; Eye Irrit. 2; STOT < 10 %
SE 3; H315, H319, H335
Xi, R36/37/38
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
Use water spray to cool unopened containers.

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to
form explosive concentrations. Vapours can accumulate in low areas.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and
place in container for disposal according to local regulations (see section 13).
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic
charge.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Recommended storage temperature: 2 - 8 °C
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, Flame retardant antistatic protective clothing, The type of protective
equipment must be selected according to the concentration and amount of the dangerous
substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: clear, liquid
Colour: colourless, yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
Heat, flames and sparks. Extremes of temperature and direct sunlight.
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: 3 - Group 3: Not classifiable as to its carcinogenicity to humans (tert-Butyl methyl ether)
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting
as this material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal
company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 2398 IMDG: 2398 IATA: 2398
UN proper shipping name
ADR/RID: METHYL tert-BUTYL ETHER, SOLUTION
IMDG: METHYL tert-BUTYL ETHER, SOLUTION
IATA: Methyl tert-butyl ether, SOLUTION
Transport hazard class(es)
ADR/RID: 3 IMDG: 3 IATA: 3
Packaging group
ADR/RID: II IMDG: II IATA: II
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
resulting from handling or from contact with the above product. See reverse side of invoice or packing
slip for additional terms and conditions of sale.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-chlorobenzylazide 在 氯化铵 、 锌 作用下， 以 乙醇 、 水 为溶剂， 生成 邻氯苯甲胺
  参考文献：
  名称：

  一种无金属的催化体系，用于氧化苄基亚甲基和 伯胺 在下面 溶剂无条件

  摘要：

  碘-吡啶–叔丁基过氧化氢 被开发为一种绿色高效的催化系统，用于将苄基亚甲基氧化为 酮类 和 伯胺 到 腈。反应条件温和，对环境无害，无过渡金属，有机溶剂或需要使用危险试剂。这氧化作用 苄基亚甲基得到相应的 酮类 具有极好的收率和完全的化学选择性，同时氧化了 伯胺 在几分钟内完成，提供了各种 腈 中等至良好的产量。

  DOI：

  10.1039/b919346b
• 作为产物：
  描述：

  邻氯苄醇 在 sodium azide 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 2-chlorobenzylazide
  参考文献：
  名称：

  使用点击化学的新型亮氨酸脲基衍生物作为氨肽酶N抑制剂。

  摘要：

  氨基肽酶N在各种恶性细胞上的过表达与肿瘤血管生成和转移有关。在该报告中，设计，合成并评估了一系列新的含有三唑部分的亮氨酸脲基衍生物，并将其评估为APN抑制剂。其中，化合物13v表现出最佳的APN抑制作用，IC50值为0.089±0.007μM，比Bestatin的IC50值低两个数量级（IC50 = 9.4±0.5μM）。化合物13v还显示出剂量依赖性的抗血管生成活性。即使在较低浓度（10μM）下，化合物13v在人脐静脉内皮细胞（HUVEC）毛细血管形成试验和大鼠胸主动脉环试验中也显示出与100μM的Bestatin相似的抗血管生成活性。此外，与Bestatin相比，13v表现出可比性，

  DOI：

  10.1016/j.bmc.2018.04.041

文献信息

• Design, synthesis, and evaluation of metronidazole-1,2,3-triazole derivatives as potent urease inhibitors
  作者：Elham Babazadeh Rezaei、Fahimeh Abedinifar、Homa Azizian、Mohammad Nazari Montazer、Mehdi Asadi、Samanesadat Hosseini、Saghi Sepehri、Maryam Mohammadi-Khanaposhtani、Mahmood Biglar、Bagher Larijani、Massoud Amanlou、Mohammad Mahdavi

  DOI：10.1007/s11696-021-01653-4

  日期：2021.8

  A new series of metronidazole-1,2,3-triazole derivatives 6a–o was synthesized and evaluated as Helicobacter pylori urease inhibitors. All the synthesized compounds were more potent than standard inhibitor thiourea against urease. Among the synthesized compounds, compound 6f (IC50 = 1.975 ± 0.25 µM) with inhibitory activity around 11-fols more than thiourea (IC50 = 22.00 ± 0.14 µM) was the most potent

  合成了一系列新的甲硝唑-1,2,3-三唑衍生物6a-o，并作为幽门螺杆菌脲酶抑制剂进行了评估。所有合成的化合物都比标准抑制剂硫脲对脲酶更有效。在合成的化合物中，化合物 6f (IC50 = 1.975 ± 0.25 µM) 的抑制活性比硫脲 (IC50 = 22.00 ± 0.14 µM) 高 11-fos 左右，是最有效的化合物。该化合物的动力学研究表明，化合物 6f 以非竞争性模式抑制脲酶。基于分子模型研究，化合物 6f 指向双镍中心，并通过 H 键和 T 形 π-π 疏水相互作用与关键残基 His492 和 Asp633 稳定。此外，它通过与His593和Arg609的相互作用锚定在活性位点腔中的螺旋-转角-螺旋基序上。最后，
• Discovery of Natural Product Derived Labdane Appended Triazoles as Potent Pancreatic Lipase Inhibitors
  作者：Renjitha Jalaja、Shyni G. Leela、Praveen K. Valmiki、Chettiyan Thodi F. Salfeena、Kizhakkan T. Ashitha、Venkata Rao D. Krishna Rao、Mangalam S. Nair、Raghu K. Gopalan、Sasidhar B. Somappa

  DOI：10.1021/acsmedchemlett.8b00109

  日期：2018.7.12

  coronary heart disease (CHD), nonalcoholic fatty liver, type 2 diabetes, etc. Pancreatic lipase plays a vital role in food fat digestion and absorption. Therefore, to control obesity, inhibition of pancreatic lipase is the active therapy. Thus, novel natural product derived labdane appended triazoles with pancreatic lipase inhibition potential were designed and synthesized. Among these hybrids, 6b and

  肥胖是导致许多代谢异常的原因，包括血脂异常，冠心病（CHD），非酒精性脂肪肝，2型糖尿病等。胰腺脂肪酶在食物脂肪的消化吸收中起着至关重要的作用。因此，控制肥胖是抑制胰腺脂肪酶的有效疗法。因此，设计并合成了具有胰脂肪酶抑制潜能的新的天然产物衍生的附有拉丹烷的三唑。在这些杂种中，6b和6f表现出优异的抑制活性（IC 50 0.75±0.02μM和0.77±0.01μM），略好于阳性对照Orlistat（IC 50 0.8±0.03μM）。化合物6c，6e和6g – j对PL的抑制作用与阳性对照相当。有趣的是，在0.5至100μM的浓度范围内，没有一种化合物显示出细胞毒性（Hep G2）。总体结果显示，附有拉丹的三唑类药物可作为减肥药。
• Synthesis of 2,4-unsubstituted quinoline-3-carboxylic acid ethyl esters from arylmethyl azides via a domino process
  作者：Jumreang Tummatorn、Charnsak Thongsornkleeb、Somsak Ruchirawat、Tanita Gettongsong

  DOI：10.1039/c3ob27493d

  日期：——

  4-unsubstituted quinoline-3-carboxylic acid ethyl esters via a domino process is described. The synthesis employs arylmethyl azides as the precursor which undergoes an acid-promoted rearrangement to give an N-aryl iminium ion. Following the addition with ethyl 3-ethoxyacrylate, intramolecular electrophilic aromatic substitution, elimination and subsequent oxidation, the quinoline products were obtained

  描述了通过多米诺法方便地合成2，4-未取代的喹啉-3-羧酸乙酯。该合成使用芳基甲基叠氮化物作为前体，该前体经历酸促进的重排以产生N-芳基亚胺鎓离子。继加3-乙氧基丙烯酸乙酯，分子内亲电芳族取代，消除和随后的氧化，喹啉产物以中等至优异的产率获得。
• 1,2,3-Triazole incorporated coumarin derivatives as potential antifungal and antioxidant agents
  作者：Mubarak H. Shaikh、Dnyaneshwar D. Subhedar、Firoz A. Kalam Khan、Jaiprakash N. Sangshetti、Bapurao B. Shingate

  DOI：10.1016/j.cclet.2015.11.003

  日期：2016.2

  A series of novel ethyl-7-((1-(benzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-oxo-2H-chromene-3-carboxylates 8a-h as potential antifungal agents were synthesized via click chemistry. The antifungal activity was evaluated against five human pathogenic fungal strains, such as Candida albicans, Fusarium oxysporum, Aspergillus flavus, Aspergillus niger and Cryptococcus neoformans. Compound 8c, 8d, 8e and 8h

  一系列新型的7-（（（1-（苄基）-1H-1,2,3-三唑-4-基）甲氧基）乙基-2-氧代-2H-色烯-3-羧酸酯8a-h作为潜在的抗真菌剂试剂通过点击化学合成。评估了对五种人类病原性真菌菌株（如白色念珠菌，尖孢镰刀菌，黄曲霉，黑曲霉和新型隐球菌）的抗真菌活性。当与咪康唑相比时，发现化合物8c，8d，8e和8h与白色念珠菌等价，而与咪康唑相比，化合物8f的活性是对白色念珠菌的两倍，对白色念珠菌而言，化合物8f与氟康唑相当。还评估了基于香豆素的三唑衍生物的抗氧化剂活性，与标准药物相比，发现化合物8a是有效的抗氧化剂。此外，对新合成的化合物进行了分子对接研究，结果表明在真菌白色念珠菌酶P450细胞色素羊毛甾醇14α-脱甲基酶的活性位点具有良好的结合模式。此外，还分析了合成的化合物的ADME特性，并显示出有可能建立良好的口服药物候选物。
• Synthesis of 1,2,3,triazole modified analogues of hydrochlorothiazide via click chemistry approach and in-vitro α-glucosidase enzyme inhibition studies
  作者：Hina Siddiqui、M. A. A. Baheej、Saeed Ullah、Fazila Rizvi、Shazia Iqbal、Haroon M. Haniffa、Atia-tul Wahab、M. Iqbal Choudhary

  DOI：10.1007/s11030-021-10314-3

  日期：2022.8

  The current study was aimed to discover potent inhibitors of α-glucosidase enzyme. A 25 membered library of new 1,2,3-triazole derivatives of hydrochlorothiazide (1) (HCTZ, a diuretic drug also being used for the treatment of high blood pressure) was synthesized through click chemistry approach. The structures of all derivatives 2–26 were deduced by MS, IR, 1H-NMR, and 13C-NMR spectroscopic techniques. All the compounds were found to be new. Compounds 1–26 were evaluated for α-glucosidase enzyme inhibition activity. Among them, 18 compounds showed potent inhibitory activity against α-glucosidase with IC50 values between 24 and 379 µM. α-Glucosidase inhibitor drug acarbose (IC50 = 875.75 ± 2.08 μM) was used as the standard. Kinetics studies of compounds 6, 9, 11, 12, 15, 20, 23, and 24 revealed that only compound 15 as a mixed-type of inhibitor, while others were non-competitive inhibitors of α-glucosidase enzyme. All the compounds were found to be non-cytotoxic when checked against mouse fibroblast 3T3 cell line.

  本研究旨在发现α-葡萄糖苷酶酶的有效抑制剂。通过点击化学方法，合成了一系列25个新型的1,2,3-三唑衍生物，这些衍生物是由氢氯噻嗪（1）（HCTZ，一种用于治疗高血压的利尿药物）衍生而来。所有衍生物2-26的结构通过MS、IR、1H-NMR和13C-NMR光谱技术推断。所有化合物均为新发现。对化合物1-26进行了α-葡萄糖苷酶酶抑制活性评估。其中，18个化合物显示出对α-葡萄糖苷酶的强抑制活性，IC50值介于24至379 µM之间。作为标准，α-葡萄糖苷酶抑制剂药物阿卡波糖（IC50 = 875.75 ± 2.08 μM）被用作对照。对化合物6、9、11、12、15、20、23和24的动力学研究表明，只有化合物15为混合型抑制剂，而其他均为非竞争性α-葡萄糖苷酶酶抑制剂。所有化合物在对小鼠成纤维细胞3T3细胞系的检测中均未显示出细胞毒性。